Skip to main content
Clinical Trials/NCT01083498
NCT01083498
Completed
Phase 2

Ablative Fractional Laser Therapy as Treatment for Becker's Nevus; a Pilot Study

Netherlands Institute for Pigment Disorders0 sites11 target enrollmentMarch 2009

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Pigmentation Disorder
Sponsor
Netherlands Institute for Pigment Disorders
Enrollment
11
Primary Endpoint
Physician's global assessment
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

The purpose of this study is to determine whether the use of ablative fractional laser is effective in the treatment of Becker's nevus.

Detailed Description

Becker's nevus (BN) is an uncommon pigment disorder of the epidermis characterized by increased pigmentation, a slightly elevated, verrucous surface of the affected skin and sometimes hyperpigmentation. No effective treatment is available. Several laser modalities have been applied in the treatment of Becker's nevus in uncontrolled studies with varying results. Recently, fractional laser therapy was suggested as treatment option for Becker's nevus. In fractional laser therapy, microscopic columns of skin are coagulated or ablated, leaving the surrounding tissue intact, which enhances healing of the treated skin. In this study, the efficacy and safety of ablative fractional laser therapy was assessed in the treatment of Becker's nevus.

Registry
clinicaltrials.gov
Start Date
March 2009
End Date
January 2010
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Netherlands Institute for Pigment Disorders

Eligibility Criteria

Inclusion Criteria

  • Becker nevus
  • Subjects attending the outpatient department of the Netherlands Institute for Pigment Disorders
  • Age at least 18 years
  • Subject is willing and able to give written informed consent

Exclusion Criteria

  • use of bleaching creams during the past six weeks
  • history of keloid
  • active eczema
  • suspected hypersensitivity to lidocaine or triple therapy
  • use of isotretinoin in the past six months
  • high exposure of the lesion to sunlight or UV light (UVA or UVB).

Outcomes

Primary Outcomes

Physician's global assessment

Time Frame: T0, 3 and 6 months follow-up

Improvement of hyperpigmentation was assessed by an independent blinded dermatologist. The results were scored on a scale from zero to six (0: total clearance (100% improvement), 1: almost total clearance (90-99% improvement), 2: distinct clearance (75-89% improvement) 3: moderate clearance (50-74% improvement) 4: mild clearance (25-49% improvement) 5: no change, 6: worsening of hyperpigmentation).

Secondary Outcomes

  • L-value(T0, 3 and six months follow-up)
  • Melanin index(T0, 3 and 6 months follow-up)
  • Patient's global assessment(3 and 6 months follow-up)
  • Patient's satisfaction(3 and 6 months follow-up)
  • Histopathologic assessment(3 months follow-up)

Similar Trials